Pregnant patients with sickle cell disease and hyperhemolysis requiring intrauterine transfusion: A challenging clinical scenario.

Pediatric Blood & CancerEarly View e30428 LETTER TO THE EDITOR Pregnant patients with sickle cell disease and hyperhemolysis requiring intrauterine transfusion: A challenging clinical scenario Elizabeth Abels, Elizabeth Abels Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USASearch for more papers by this authorThomas C. Binns, Thomas C. Binns Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USASearch for more papers by this authorNataliya Sostin, Nataliya Sostin Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USASearch for more papers by this authorKristin Stendahl, Kristin Stendahl Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USASearch for more papers by this authorChristopher A. Tormey, Christopher A. Tormey Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USASearch for more papers by this authorJeremy W. Jacobs, Corresponding Author Jeremy W. Jacobs [email protected] orcid.org/0000-0002-5719-9685 Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA Correspondence Jeremy W. Jacobs, 55 Park St, New Haven, CT, 06511, USA. Email: [email protected]Search for more papers by this author Elizabeth Abels, Elizabeth Abels Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USASearch for more papers by this authorThomas C. Binns, Thomas C. Binns Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USASearch for more papers by this authorNataliya Sostin, Nataliya Sostin Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USASearch for more papers by this authorKristin Stendahl, Kristin Stendahl Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USASearch for more papers by this authorChristopher A. Tormey, Christopher A. Tormey Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USASearch for more papers by this authorJeremy W. Jacobs, Corresponding Author Jeremy W. Jacobs [email protected] orcid.org/0000-0002-5719-9685 Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA Correspondence Jeremy W. Jacobs, 55 Park St, New Haven, CT, 06511, USA. Email: [email protected]Search for more papers by this author First published: 17 May 2023 https://doi.org/10.1002/pbc.30428Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1Danaee A, Inusa B, Howard J, Robinson S. Hyperhemolysis in patients with hemoglobinopathies: a single-center experience and review of the literature. Transfus Med Rev. 2015; 29: 220- 230. doi:10.1016/j.tmrv.2015.06.001 2Jacobs JW, Stephens LD, Allen ES, et al. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: a systematic review. Br J Haematol. 2023. doi:10.1111/bjh.18825 3Test ST, Woolworth VS. Defective regulation of complement by the sickle erythrocyte: evidence for a defect in control of membrane attack complex formation. Blood. 1994; 83: 842- 852. 4Mwesigwa S, Moulds JM, Chen A, et al. Whole-exome sequencing of sickle cell disease patients with hyperhemolysis syndrome suggests a role for rare variation in disease predisposition. Transfusion (Paris). 2018; 58: 726- 735. doi:10.1111/trf.14431 5Chadebech P, Habibi A, Nzouakou R, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion (Paris). 2009; 49: 1785- 1792. doi:10.1111/j.1537-2995.2009.02199.x 6Habibi A, Mekontso-Dessap A, Guillaud C, et al. Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes. Am J Hematol. 2016; 91(10): 989- 994. doi:10.1002/ajh.24460 7Smith-Whitley K. Complications in pregnant women with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2019; 2019(1): 359- 366. doi:10.1182/hematology.2019000039 8Costa MFH, Torres LC, Matta MCD, Araújo ADS, Souza AI. Interleukin-6 in pregnancy with sickle cell disease. Hematol Transfus Cell Ther. 2019; 41(4): 298- 302. doi:10.1016/j.htct.2019.02.001 9Abu-Raya B, Michalski C, Sadarangani M, Lavoie PM. Maternal immunological adaptation during normal pregnancy. Front Immunol. 2020; 11:575197. doi:10.3389/fimmu.2020.575197 10Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020; 4(2): 327- 355. doi:10.1182/bloodadvances.2019001143 11Sarno L, Tufano A, Maruotti GM, Martinelli P, Balletta MM, Russo D. Eculizumab in pregnancy: a narrative overview. J Nephrol. 2019; 32: 17- 25. doi:10.1007/s40620-018-0517-z 12 Truxima package insert. Accessed January 13, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761088s018lbl.pdf 13Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011; 117(5): 1499- 1506. doi:10.1182/blood-2010-07-295444 14D'Mello RJ, Hsu CD, Chaiworapongsa P, Chaiworapongsa T. Update on the use of intravenous immunoglobulin in pregnancy. Neoreviews. 2021; 22(1): e7- e24. doi:10.1542/neo.22-1-e7 15Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am. 2017; 43: 489- 502. doi:10.1016/j.rdc.2017.04.013 16Shah N, Lipato T, Alvarez O, et al. Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis. Expert Rev Hematol. 2022; 15(2): 167- 173. doi:10.1080/17474086.2022.2031967 17 Oxbryta package insert. Accessed April 26, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf Early ViewOnline Version of Record before inclusion in an issuee30428 ReferencesRelatedInformation